Latest News and Press Releases

Marseille, France, March 25, 2025 4:30 p.m. EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized Phase I/II study EVICTION at the...

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...

ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer Marseille, France, November 5, 2024, 3 pm CET – ImCheck Therapeutics...

ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...

ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...

FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030...

ImCheck Appoints Stephan Braun as Chief Medical Officer         Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...

ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...

ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting          Marseille, France, October 30, 2023 – ImCheck...